Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with aids and cytomegalovirus retinitis

Journal of Infectious Diseases

Volumn 172, Issue 4, 1995, Pages 951-956

  Arevalo, J Fernando ^a,b   Gonzalez, Casimiro ^a,b   Capparelli, Edmund V ^a,b   Kirsch, Leonard S ^a,b   Garcia, Roberto F ^a,b   Quiceno, Jose I ^a,b   Connor, James D ^a,b   Gambertoglio, John ^a,b   Bergeron Lynn, Germaine ^a,b   Freeman, William R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD RETINA BARRIER; CILIARY DISK; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA DETACHMENT; RETINITIS; VITRECTOMY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CYTOMEGALOVIRUS RETINITIS; DRUG THERAPY, COMBINATION; FEMALE; FOSCARNET; GANCICLOVIR; HUMAN; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RETINAL DETACHMENT; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VITREOUS BODY;

EID: 0029093244     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/172.4.951     Document Type: Article

References (33)

1. Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscamet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20
2. Henderly DE, Freeman, WR, Causey DM, Rao NA. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987;94:425-34
3. LeHoang P, Girard B, Robinet M, et al. Foscamet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989;96:865-73
4. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9
5. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal gan ciclovir concentration after intravenous administration in acquired immunodeficiency syndrome patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993; 168:1506-9
6. Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA, Gambertoglio JG. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1990;525:133-40
7. Freeman WR, Quiceno JI, Crapotta JA, Listhaus A, Munguia D, Aguilar MF. Surgical repair of rhegmatogenous retinal detachment in immuno-suppressed patients with cytomegalovirus retinitis. Ophthalmology 1992;99:466-74
8. Abel R Jr, Boyle GL, Furman M, Leopold IH. Intraocular penetration of cefazoline sodium in rabbits. Am J Ophthalmol 1974;78:779-87
9. Martin DF, Ficker LA, Aguilar HA, Gardner SK, Wilson LA, Meredith TA. Vitreous cefazolin levels after intravenous injection: effects of inflammation, repeated antibiotic doses, and surgery. Arch Ophthalmol 1990;108:411-4
10. Palestine AG, Stevens G Jr, Lane HC, et al. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol 1986;101:95-101
11. Jabs DA, Newman C, De Bustros S, Polk BF. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987;94:824-30
12. Gross JG, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1990;97:681-6
13. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivities of clinicalisolates ofhuman cytomegalovirus to 9-(1, 3-dihydroxy-2-propoxymeth-yl)guanine. J Infect Dis 1985;152:833-4
14. Jabs DA, Wingard JR, De Bustros S, de Miranda P, Saral R, Santos GW. BW B759U for cytomegalovirus retinitis: intraocular drug penetration. Arch Ophthalmol 1986;104:1436-7
15. Felsenstein D, d’Amico DJ, Hirsch MS, et al. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1 (hydroxymethyl)ethoxymethyl]gua-nine. Ann Intern Med 1985;103:377-80
16. Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103:368-73
17. Mar EC, Cheng YC, Huang ES. Effect of 9-(l, 3-dihydroxy-2-propoxy-methyl)guanine on human cytomegalovirus replication in vitro. Antimi-crob Agents Chemother 1983;24:518-21
18. Tyms AS, Davis JM, Jeffries DJ, Meyers JD. BW759U, an analog of acyclovir, inhibits human cytomegalovirus in vitro. Lancet 1984;2:924-5
19. Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-61
20. Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutantresistant to the nucleoside analog 9-([2-hydroxy-l-(hydroxymethyl)eth-oxymethyl])guanine (BW B795U) induces reduced levels of BW B795U triphosphate. Proc Natl Acad Sci USA 1986;83:8769-73
21. Wahren B, Oberg B. Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology 1980; 14:7-15
22. Kane A, Barza M, Baum J. Intravitreal injection of gentamicin in rabbits: effects of inflammation and pigmentation on half-life and ocular distribution. Invest Ophthalmol Vis Sci 1981;20:593-7
23. Cobo LM, Forster RK. The clearance of intravitreal gentamicin. Am J Ophthalmol 1981;92:59-62
24. Barza M, Kane A, Baum J. Pharmacokinetics of intravitreal carbenicillin, cefazolin and gentamicin in rhesus monkeys. Invest Ophthalmol Vis Sci 1983;24:1602-6
25. Flicker L, Meredith TA, Gardner S, Wilson LA. Cefazolin levels after intravitreal injection. Invest Ophthalmol Vis Sci 1990;30:502-5
26. Sharir M, Triester G, Kneer J, Rubinstein E. The intravitreal penetration of ceftriaxone in man following systemic administration. Invest Ophthalmol Vis Sci 1989;30:2179-83
27. Keren G, Alhalel A, Bartov E, et al. The intravitreal penetration of orally administered ciprofloxacin in humans. Invest Ophthalmol Vis Sci 1991;32:2388-92
28. Bron AM, Pechinot AP, Garcher CP, et al. The ocular penetration of oralsparfloxacin in humans. Am J Ophthalmol 1994;117:322-7
29. Shulman JA, Peyman GA, Fiscella RG, Pulido J, Sugar J. Parenterally administered acyclovir for viral retinitis associated with AIDS [letter]. Arch Ophthalmol 1984; 102:1750
30. Henry K, Cantrill H, Fletcher C, Chinnock BJ, Balfour HH. Use of intra-vitreal ganciclovir (dihydroxy popoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103:1723
31. Ben-Nun J, Joyce DA, Cooper RL, Cringle SJ, Constable IJ. Pharmacokinetics of intravitreal injection assessment of a gentamicin model by ocular dialysis. Invest Ophthalmol Vis Sci 1989;30:1055-61
32. Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986;40:281-6
33. Flores-Aguilar M, Kuppermann BD, Quiceno JI, et al. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology 1993;100:1022-31